Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
- 1 June 1999
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 10 (6), 655-661
- https://doi.org/10.1023/a:1008389119525
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1997
- IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's LymphomaBlood, 1997
- Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrowBlood, 1994
- Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20Blood, 1994
- Expression in Non-Hodgkin's Lymphoma of thebcl-2 Protein Associated with the t(14;18) Chromosomal TranslocationNew England Journal of Medicine, 1988
- The gene located at chromosome 18 band q21 is rearranged in uncultured diffuse lymphomas as well as follicular lymphomasBlood, 1987
- Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytesEuropean Journal of Immunology, 1986
- Role of the Bp35 cell surface polypeptide in human B-cell activation.Proceedings of the National Academy of Sciences, 1985
- Distinctive Chromosomal Abnormalities in Histologic Subtypes of Non-Hodgkin's LymphomaNew England Journal of Medicine, 1982
- Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype AntibodyNew England Journal of Medicine, 1982